Skystar Bio-Pharmaceutical Signs New Contracts and Letters of Intent at the 19th Henan Province Poultry Trade Show

XI'AN, China, Sept. 27 /Xinhua-PRNewswire-FirstCall/ -- Skystar Bio-Pharmaceutical Co., Ltd. (OTC Bulletin Board: SKBI) a leading bio-pharmaceutical company in the People's Republic of China ("PRC"), today announced that it signed over 100 new contracts valued at approximately $667,000 in revenue for the remainder of 2007. In addition, they successfully secured over 400 Letter(s) of Intent with distributors and end-customers.

Skystar obtained these contracts and letters of intent while attending the 19th Henan Province Poultry Trade Show organized by the Henan Stock Breeding Bureau and Henan Poultry Industry Association on September 15th and 16th. The tradeshow is one of the most significant regional tradeshows. It was attended by over 1,000 producers from 30 provinces and municipalities in China as well as producers from the U.S., the Netherlands, Germany, and Japan. This year's event had record attendance and included more than 10,000 conference representatives and 100,000 visitors.

"At the conference, we received an overwhelming amount of interest in our product lines, particularly our new Swine High-Fever Syndrome first aid kit and Cure King," commented Mr. Weibing Lu, CEO and Chairman of Skystar. "This was a very important tradeshow with producers and customers from various Chinese provinces and countries attending the event to discuss and exchange the latest trends and developments in the animal husbandry and veterinary medicine industry. We believe we made full use of this show to secure new customer contracts, develop important industry relationships and improve Skystar's brand reputation."

Since Skystar successfully launched its first aid kit for Swine High-Fever Syndrome ("SHFS") in July, the Company's visibility has significantly increased within the bio-pharmaceutical industry. The SHFS kit has been clinically proven to be highly effective in restraining secondary infections resulting from porcine reproductive and respiratory syndrome, also known as blue ear disease. Many farmers and distributors visited Skystar's booth at the trade show to obtain introductory materials on this product as well as many of Skystar's other products.

Skystar also received strong interest in its new "Cure King" package of selected GMP-approved veterinary medicines that cover many common animal diseases including respiratory and digestive system ailments. Since the market debut of "Cure King" at the beginning of August, the product has had strong sales due to its efficiency and effectiveness in treating a combination of diseases simultaneously. Skystar received numerous letters of intent for the purchase of the "Cure King" series at the tradeshow.

Skystar also plans to attend the 2007 Shandong Province Stock Breeding Expo organized by Shandong Stock Breeding Bureau and Shandong Stock Breeding Association from October 24th - 28th.

About Skystar Bio-Pharmaceutical

Skystar Bio-Pharmaceutical Company is a China-based producer and distributor of vaccines, microorganisms and veterinary medication to cure and prevent disease in poultry, livestock, birds and pets. The Company's product line consists of more than 100 products with over 50 additional products in the developmental stage. Skystar has formed strategic sales distribution networks throughout China. The Company recently completed construction of new state-of-the-art bio-pharmaceutical facilities covering an area of almost eight acres. The new facilities meet or exceed all Good Manufacturing Practice (GMP) Certification Standards and have received GMP Certification from the Chinese government. For additional information, please visit http://www.skystarbio-pharmaceutical.com .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are based upon the current beliefs and expectations of management and are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Such factors include, but are not limited to the Company's ability to develop new products, market acceptance of the company's new products, ability to obtain the regulatory approvals or clearances that are necessary to commercialize its products, ability to protect proprietary rights, political and economic factors in the People's Republic of China and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please contact:

Scott Cramer

Skystar Bio-Pharmaceutical Co., Ltd

Director -- U.S. Representative

Tel: +1-407-645-4433

Email: scramer@skystarbio-pharmaceutical.com

CCG Elite Investor Relations

Crocker Coulson, President

Email: crocker.coulson@ccgir.com

Leslie Richardson, Financial Writer

Tel: +1-310-231-8600 x122

Email: leslie.richardson@ccgir.com